FDA 510(k) Hybrid Delivery Planner
This page helps device teams design a practical hybrid operating model where AI handles structured production work and consultants focus on high-risk regulatory judgment. Use the tools below to set scope, cost, and cadence before kickoff.
The output is planning guidance, not legal advice. Teams should still align final strategy and claims with qualified regulatory professionals.
When Hybrid Delivery Creates Real Value
AI is strongest for repeatable structure
- eSTAR section drafting with consistent formatting and traceability.
- Evidence inventory tracking across test reports, labeling, and risk files.
- Version control and rapid iteration after internal review cycles.
Consultants are strongest for reviewer-facing judgment
- Classification and product code strategy when pathway uncertainty exists.
- Predicate rationale and substantial equivalence positioning.
- Deficiency-response strategy and FDA communication planning.
If your team has only one expert, assign that person to risk decisions and reviewer narratives, then automate low-variance assembly tasks. That usually improves both speed and decision quality.
Tool 1: AI vs Consultant Work Allocation Estimator
Score five project conditions to estimate how many hours should be consultant-led versus AI-assisted production. This helps prevent overpaying for drafting while keeping strategic tasks covered.
Tool 2: Consultant SOW and Budget Envelope Estimator
Build a scoped consultant engagement around strategic tasks instead of full drafting. This estimator produces an SOW-ready hour and cost envelope so teams can evaluate proposals consistently.
Choose consultant-owned work packages
| Package | Why consultant-owned | Hours (typical range) | Include |
|---|---|---|---|
| Pathway and product code strategy | High impact on review pathway and claims framing. | 8-20 | |
| Predicate strategy and SE narrative review | Core reviewer-facing argument quality control. | 12-32 | |
| Test gap disposition and evidence rationale | Prevents weak justifications and late-cycle rework. | 10-28 | |
| Submission quality and RTA checkpoint | Completeness and consistency before filing. | 8-18 | |
| FDA interaction and response drafting oversight | Critical for response framing under time pressure. | 12-36 |
Hybrid Governance Checklist for 510(k) Teams
Controls that keep AI output submission-ready
- Use source-traceable evidence references for each critical claim.
- Assign named reviewers for indications, technological characteristics, and test conclusions.
- Run a pre-submit RTA-style completeness sweep against required sections and attachments.
Controls that keep consultants efficient
- Route consultant time to decisions, not formatting tasks.
- Define a 48-hour SLA for team feedback cycles on consultant comments.
- Use a single issue log for open strategy questions, owners, and due dates.
Primary References
Use these FDA and eCFR sources as the governing baseline when tailoring your hybrid execution plan:
- 21 CFR 807.87, information required in a premarket notification submission
- FDA Refuse to Accept (RTA) Policy for 510(k)
- FDA selecting and preparing the correct premarket submission
- FDA eSTAR program overview
- FDA 510(k) premarket notification overview
Planning note: annual user-fee values and review timing assumptions change over time. Validate your latest numbers against current FDA publications before budget approval.
Need a Faster 510(k) Kickoff Plan?
If your team wants this converted into a concrete delivery plan, use our core 510(k) submission services page to align on scope, staffing, and filing sequence.